1. Articles from PR Newswire

    prnewswire.com

  2. 1-4 of 4
    1. Yissum Launches NanoTech Fund

      Yissum Launches NanoTech Fund

      JERUSALEMOct. 9, 2018 /PRNewswire/ -- Yissum, The Technology Transfer Company of The Hebrew University of Jerusalem, announced today the launch of its new NanoTech Fund which will focus exclusively on promising innovations emerging from Hebrew University's elite nanotech research. The Fund has already secured $6M from top international strategic and institutional investors, and will raise up to $9M.

      The NanoTech Fund will focus on smart materials and nanotechnologies, funding deep technologies offering integrated solutions in the areas of 3D printing, quantum science, and renewable energy. As the global nanomaterials and nanotech markets continue to grow, the fund will ensure ...

      Read Full Article
    2. Therapix Biosciences Plans Preclinical Study to Evaluate Opioid-Sparing Effects of Two Innovative Synthetic Cannabinoids

      Therapix Biosciences Plans Preclinical Study to Evaluate Opioid-Sparing Effects of Two Innovative Synthetic Cannabinoids

      /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based treatments, executed a non-exclusive material transfer agreement with Yissum, the technology transfer company of The , for two synthetic cannabinoids synthesized by , Ph.D., Professor of medicinal chemistry at the university and Chairman of the Therapix Scientific Advisory Board. Therapix plans to initiate a preclinical study during the fourth quarter to evaluate the opioid-sparing effect of these compounds in a rat model. The opioid overuse epidemic in was recently declared a public health emergency by President . According to Medical Care, prescription opioid overdose, abuse ...

      Read Full Article
      Mentions: Medicine/Health
    3. CIITECH Sponsors Research Project on Cannabis-based Therapy for Asthma at the Multidisciplinary

      CIITECH Sponsors Research Project on Cannabis-based Therapy for Asthma at the Multidisciplinary

      LONDON and TEL AVIV, Israel, October 24, 2017 /PRNewswire/ 

      CIITECH, a UK-Israel cannabis biotech startup, announced today that it has selected to sponsor a research project with the Multidisciplinary Center on Cannabinoid Research of the Hebrew University of Jerusalem, focused on the therapeutic benefit of cannabis for the treatment of asthma.

      CIITECH selected to award research funding, through a non-exclusive grant competition, to the collaborative work of Professor Raphael Mechoulam, a pioneer in the field of cannabis research credited for the discovery of the endocannabinoid system, and his colleague, Professor Francesca Levi-Schaffer, a global expert in asthma research. Together, these ...

      Read Full Article
      Mentions: Medicine/Health
    4. Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of

      Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of

      "We appreciate and continue to benefit from BARDA's ongoing support in the development of Reltecimod as a novel, host-based, immunomodulatory therapy to treat severe infections," said Dan Teleman, Chief Executive Officer of Atox Bio. "We have a very collaborative partnership with BARDA and look forward to continuing to work together." Reltecimod (AB103) is a rationally designed peptide that binds to the CD28 co-stimulatory receptor to modulate the host's immune response to severe infections. By limiting, but not inhibiting, the body's acute inflammatory response, Reltecimod helps control the cytokine storm that could quickly lead to morbidity and mortality ...

      Read Full Article
      Mentions: Yissum
    1-4 of 4
  1. Categories

    1. News:

      News, Placeholder